Overview

A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease

Status:
Not yet recruiting
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy and safety of astegolimab compared with placebo in participants with chronic obstructive pulmonary disease (COPD) who are former or current smokers and have a history of frequent exacerbations.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Hoffmann-La Roche
Treatments:
Astegolimab